KPI data tables

Zealand Pharma operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Zealand Pharma Cash Position (dkk_millions)
PeriodCash, cash equivalents and marketable securities
H1 202614,457
YE 202515,109

Source: Zealand Pharma H1 2026 results: cash position DKK 14,457 million versus DKK 15,109 million. Zealand Pharma Company announcement No. 39 / 2026, 13 Aug 2026: https://via.ritzau.dk/files/90446/15088867/497323/en

Zealand Pharma Partnership Economics: Annual Revenue by Partner (DKK millions)
PeriodBoehringer Ingelheim (survodutide)Roche (petrelintide, from 2025)Sanofi (lixisenatide, legacy royalty)Other partnerships + grants
2024504018
202322407049
20221007024
20211008019
2020149015054

Source: Zealand Pharma annual + half-year reports (zealandpharma.com IR; OMX Copenhagen filings; ZEAL.CO); milestone-receipt company announcements (BI ~EUR 20M 2020, BI ~EUR 30M 2023, Sanofi ~USD 10M 2023); Roche-Zealand petrelintide licensing announcement (March 12, 2025). Total annual revenue matches reported figures; the per-partner split is estimated from disclosed milestone events because Zealand does not itemize partner-level revenue every year. DKK/USD approx 1 USD = ~6.8 DKK.

Zealand Roche Milestone Revenue H1 2026 (dkk_millions)
PeriodPetrelintide Phase 3 initiation milestoneRoche first anniversary payment
H1 20263,671798

Source: Zealand Pharma H1 2026 results: revenue DKK 4,525 million; Phase 3 initiation USD 575 million (DKK 3,671 million); anniversary USD 125 million (DKK 798 million). https://via.ritzau.dk/files/90446/15088867/497323/en.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Zealand Pharma (ZEAL.CO) - KPIs | Sterling